With thousands of gene and cell therapies in the pipeline, health systems should make sure they are for these drugs, which can cost millions per dose, according to the American Society of ...

As financial pressures intensify across health systems, Renton, Wash.-based Providence is grappling with the combined strain of high-cost therapies, slow biosimilar uptake, shrinking reimbursement and ...